{"id":"estrogen-vaginal-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaginal irritation or burning"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Vaginal bleeding or spotting"}]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The cream formulation allows topical application of estrogen to the vaginal epithelium, where it is absorbed locally to restore tissue elasticity, moisture, and blood flow. This addresses vaginal dryness, irritation, and dyspareunia associated with menopause or estrogen deficiency. The localized delivery minimizes systemic absorption compared to oral or transdermal estrogen.","oneSentence":"Estrogen vaginal cream delivers estrogen directly to vaginal tissues to restore estrogen levels and relieve symptoms of vaginal atrophy and genitourinary syndrome of menopause.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:28.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vaginal atrophy and genitourinary syndrome of menopause"},{"name":"Vaginal dryness and dyspareunia in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT05672901","phase":"NA","title":"Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause","status":"RECRUITING","sponsor":"Stratpharma AG","startDate":"2023-04-04","conditions":"Genitourinary Syndrome of Menopause","enrollment":100},{"nctId":"NCT05317364","phase":"PHASE4","title":"Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2022-07-14","conditions":"Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence","enrollment":38},{"nctId":"NCT06353269","phase":"PHASE4","title":"Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2024-06-14","conditions":"Recurrent Urinary Tract Infection, Hypoestrogenism","enrollment":111},{"nctId":"NCT06873971","phase":"NA","title":"Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2025-12-10","conditions":"Genitourinary Syndrome of Menopause","enrollment":60},{"nctId":"NCT07260825","phase":"PHASE2, PHASE3","title":"Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"TriHealth Inc.","startDate":"2025-12","conditions":"Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva","enrollment":44},{"nctId":"NCT01886794","phase":"PHASE4","title":"Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-06-06","conditions":"Pelvic Floor Disorders","enrollment":7},{"nctId":"NCT05472779","phase":"PHASE2","title":"Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"Stephanie Wang Zuo","startDate":"2023-01-03","conditions":"Recurrent Urinary Tract Infection","enrollment":114},{"nctId":"NCT07030426","phase":"PHASE3","title":"Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2025-10-01","conditions":"Pelvic Organ Prolapse (POP)","enrollment":180},{"nctId":"NCT06969326","phase":"PHASE3","title":"Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy","status":"RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-01","conditions":"Postoperative Bleeding, Gender Dysphoria, Hysterectomy","enrollment":48},{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Urinary Bladder, Overactive, Effect of Drug","enrollment":200},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Effect of Drug, Urinary Bladder, Overactive","enrollment":300},{"nctId":"NCT02218463","phase":"NA","title":"Treatment of Prepubertal Labial Adhesions","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2014-09","conditions":"Prepubertal Labial Adhesions","enrollment":43},{"nctId":"NCT06808347","phase":"PHASE4","title":"Difference in Serum Estrogen Level Based on Methods of Vaginal Estrogen Application (fingertip Vs Applicator Use) in Post-menopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2025-02-01","conditions":"Postmenopausal Atrophic Vaginitis, Genitourinary Syndrome of Menopause","enrollment":110},{"nctId":"NCT06633705","phase":"PHASE4","title":"Changes in Neighbouring Microbiota in Genitourinary Syndrome","status":"COMPLETED","sponsor":"Koc University Hospital","startDate":"2023-11-10","conditions":"Genitourinary Syndrome of Menopause","enrollment":31},{"nctId":"NCT01648751","phase":"NA","title":"Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse","status":"TERMINATED","sponsor":"Pamela Moalli","startDate":"2012-05","conditions":"Pelvic Organ Prolapse","enrollment":21},{"nctId":"NCT05221021","phase":"PHASE4","title":"Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2022-10-01","conditions":"Overactive Bladder Syndrome","enrollment":152},{"nctId":"NCT06425978","phase":"PHASE4","title":"Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit","status":"RECRUITING","sponsor":"Fundación Santiago Dexeus Font","startDate":"2024-05-30","conditions":"Genitourinary Syndrome of Menopause","enrollment":192},{"nctId":"NCT03996603","phase":"PHASE4","title":"Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-08-01","conditions":"Female Urogenital Diseases, Vaginal Atrophy, Postmenopausal Atrophic Vaginitis","enrollment":25},{"nctId":"NCT04301934","phase":"NA","title":"Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-06-01","conditions":"Urinary Tract Infections","enrollment":12},{"nctId":"NCT06031493","phase":"PHASE4","title":"A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2025-01","conditions":"Cervical Cancer, Sexual Dysfunction, Quality of Life","enrollment":122},{"nctId":"NCT04544475","phase":"NA","title":"A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-09-01","conditions":"Genitourinary Syndrome of Menopause (GSM)","enrollment":49},{"nctId":"NCT02431897","phase":"PHASE4","title":"Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-12","conditions":"Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse","enrollment":206},{"nctId":"NCT04487392","phase":"PHASE2","title":"Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women.","status":"WITHDRAWN","sponsor":"University of Nove de Julho","startDate":"2020-12-15","conditions":"Vulvovaginal Atrophy","enrollment":""},{"nctId":"NCT05863975","phase":"PHASE4","title":"Treatment of HPV Infection in Perimenopausal and Postmenopausal Women","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-07-01","conditions":"HPV Infection","enrollment":150},{"nctId":"NCT05458375","phase":"EARLY_PHASE1","title":"Vaginal Estradiol Use in Pessary Care","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2022-12-29","conditions":"Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina","enrollment":11},{"nctId":"NCT05118685","phase":"PHASE1","title":"Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2021-11-13","conditions":"Atrophic Vaginitis, Postmenopausal Atrophic Vaginitis","enrollment":100},{"nctId":"NCT05464654","phase":"NA","title":"Vaginal Biorevitalization With Polydeoxyribonucleotides for the Improvement of the Genitourinary Syndrome of Menopause","status":"COMPLETED","sponsor":"Hospital Regional 1o de Octubre","startDate":"2021-06-23","conditions":"Genitourinary Syndrome of Menopause, Postmenopausal Disorder, Menopause","enrollment":136},{"nctId":"NCT02213757","phase":"PHASE4","title":"Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)","status":"TERMINATED","sponsor":"Medstar Health Research Institute","startDate":"2014-08","conditions":"Microscopic Hematuria","enrollment":29},{"nctId":"NCT03943823","phase":"PHASE4","title":"Postmenopausal Pessary Users: Estrogen Versus Trimosan","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-05-07","conditions":"Vaginosis, Vaginosis, Bacterial, Vaginal Discharge","enrollment":4},{"nctId":"NCT03295487","phase":"PHASE2, PHASE3","title":"ToT and Estrogen in Postmenopausal Females","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2017-03-01","conditions":"Stress Urinary Incontinence, Postmenopausal Disorder","enrollment":210},{"nctId":"NCT04606550","phase":"NA","title":"MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study","status":"WITHDRAWN","sponsor":"Mount Sinai Hospital, Canada","startDate":"2021-09-01","conditions":"Breast Cancer Female, Genitourinary Syndrome of Menopause","enrollment":""},{"nctId":"NCT03996057","phase":"PHASE4","title":"Methenamine in a Non-antibiotic, Multimodal Approach to UTI Prevention","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2018-06-20","conditions":"UTI, Female Urogenital Diseases, UTI - Lower Urinary Tract Infection","enrollment":""},{"nctId":"NCT01816139","phase":"PHASE3","title":"Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2013-01-31","conditions":"Vulvovaginal Atrophy","enrollment":576},{"nctId":"NCT03493126","phase":"PHASE4","title":"Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2018-10-15","conditions":"Vaginal Atrophy","enrollment":59},{"nctId":"NCT02835846","phase":"PHASE4","title":"Investigation of the Effect of the Female Urinary Microbiome on Incontinence","status":"COMPLETED","sponsor":"Loyola University","startDate":"2016-09","conditions":"Overactive Bladder, Incontinence, Nocturia","enrollment":35},{"nctId":"NCT02869165","phase":"PHASE4","title":"Vaginal and Urinary Microbiome Trial","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2017-01","conditions":"Atrophic Vaginitis, Menopause, Recurrent Urinary Tract Infections","enrollment":110},{"nctId":"NCT02524769","phase":"NA","title":"The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides","status":"COMPLETED","sponsor":"Loyola University","startDate":"2015-12","conditions":"Overactive Bladder","enrollment":27},{"nctId":"NCT01123135","phase":"NA","title":"The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2009-07","conditions":"Stress Urinary Incontinence","enrollment":""},{"nctId":"NCT04717245","phase":"NA","title":"Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-10-25","conditions":"Vaginal Atrophy","enrollment":75},{"nctId":"NCT03779633","phase":"PHASE4","title":"Preoperative Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-02-02","conditions":"Pelvic Organ Prolapse","enrollment":120},{"nctId":"NCT01958073","phase":"PHASE4","title":"Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-10","conditions":"Recurrent Urinary Tract Infection","enrollment":35},{"nctId":"NCT04393194","phase":"PHASE4","title":"The Effect of Intra-vaginal Conjugated Estrogen Cream on Ring Pessary Use for Pelvic Organ Prolapse","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-05-24","conditions":"Pelvic Floor Prolapse","enrollment":420},{"nctId":"NCT02691936","phase":"NA","title":"Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2016-03","conditions":"Atrophic Vaginitis, Menopause","enrollment":69},{"nctId":"NCT03266926","phase":"","title":"Does the Use of Bupivacaine Soaked Vaginal Packing Following Vaginal Surgery Decrease Postoperative Pain?","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2017-02-01","conditions":"Pelvic Organ Prolapse, Postoperative Pain","enrollment":140},{"nctId":"NCT03032848","phase":"PHASE4","title":"Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients","status":"COMPLETED","sponsor":"Universidade Federal do Paraná","startDate":"2013-11-26","conditions":"Vaginitis Atropic, Pelvic Organ Prolapse, Endometrial Hyperplasia","enrollment":69},{"nctId":"NCT01843166","phase":"NA","title":"Vaginal Estrogen With Pessary Treatment","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Vaginal Infection, Urinary Tract Infection, Quality of Life","enrollment":150},{"nctId":"NCT02860897","phase":"PHASE4","title":"Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery","status":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-07","conditions":"Estrogen, Menopause, Pelvic Floor Disorders","enrollment":""},{"nctId":"NCT02269826","phase":"NA","title":"Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness","status":"COMPLETED","sponsor":"Dr. August Wolff GmbH & Co. KG Arzneimittel","startDate":"2008-02","conditions":"Vaginal Dryness","enrollment":117},{"nctId":"NCT03018106","phase":"PHASE4","title":"Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction","status":"TERMINATED","sponsor":"Emory University","startDate":"2017-06-30","conditions":"Sexual Dysfunction, Physiological","enrollment":1},{"nctId":"NCT01613170","phase":"PHASE4","title":"Premarin Versus Toviaz for Treatment of Overactive Bladder","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"2012-04","conditions":"Overactive Bladder","enrollment":90},{"nctId":"NCT02419729","phase":"PHASE3","title":"Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy","status":"COMPLETED","sponsor":"Faculdade de Medicina do ABC","startDate":"2015-03","conditions":"Vulvovaginal Atrophy","enrollment":45},{"nctId":"NCT02458001","phase":"NA","title":"Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer","status":"UNKNOWN","sponsor":"University College, London","startDate":"2015-07","conditions":"Cervical Cancer, Ovarian Cancer, Uterine Cancer","enrollment":100},{"nctId":"NCT00803335","phase":"PHASE3","title":"The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse","status":"COMPLETED","sponsor":"TriHealth Inc.","startDate":"2008-12","conditions":"Pelvic Organ Prolapse, Vaginal Atrophy","enrollment":54},{"nctId":"NCT01813162","phase":"PHASE1","title":"In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products","status":"COMPLETED","sponsor":"CONRAD","startDate":"2013-12","conditions":"HIV Prevention","enrollment":101},{"nctId":"NCT00361569","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2006-08","conditions":"Menopause","enrollment":622},{"nctId":"NCT01778985","phase":"PHASE4","title":"Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-12","conditions":"Pelvic Organ Prolapse, Menopause","enrollment":30},{"nctId":"NCT00908570","phase":"PHASE1","title":"Topical Estriol for Vaginal Health","status":"COMPLETED","sponsor":"Gynuity Health Projects","startDate":"2009-06","conditions":"Vaginal Health","enrollment":104},{"nctId":"NCT00484107","phase":"","title":"Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-09","conditions":"Postmenopause","enrollment":200},{"nctId":"NCT00167921","phase":"PHASE1","title":"Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Atrophic Vaginitis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"URINARY TRACT INFECTION"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"MYALGIA"},{"count":2,"reaction":"PAIN IN EXTREMITY"},{"count":2,"reaction":"PARAESTHESIA"},{"count":2,"reaction":"PRODUCT QUALITY ISSUE"},{"count":1,"reaction":"ACNE"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BINGE EATING"}],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Estrace Cream","Premarin Cream"],"phase":"marketed","status":"active","brandName":"Estrogen vaginal cream","genericName":"Estrogen vaginal cream","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estrogen vaginal cream delivers estrogen directly to vaginal tissues to restore estrogen levels and relieve symptoms of vaginal atrophy and genitourinary syndrome of menopause. Used for Vaginal atrophy and genitourinary syndrome of menopause, Vaginal dryness and dyspareunia in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}